JonesResearch downgraded Monopar Therapeutics (MNPR) to Hold from Buy without a price target following the Q4 report. The firm remains “enthusiastic” about the potential of both in-licensed ALXN-1840 in Wilson’s disease and earlier stage MNPR-101-Lu. However, it believes the company is fairly valued at current levels and that it is unlikely to increase substantially in price until the new drug application submission for ALXN-1840 approaches in 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating
- Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook
- Monopar Therapeutics sees cash runway through December 31, 2026
- Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year
- Buy Rating for Monopar Therapeutics Inc. Driven by Strategic Acquisition and ALXN1840 Potential
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue